Altimmune

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Altimmune reports positive trial results and financial stability in Q4

Altimmune's Q4 2022 performance showcased positive trial results for pemvidutide, despite financial challenges from negligible revenue.
The company's strengths lie in promising drug outcomes, strong cash reserves, and differentiated trial approaches.
Challenges include revenue generation, financial pressures, regulatory discussions, and dosing decisions for NASH treatment.
Opportunities exist in attracting investors, showcasing broader drug impact, enhancing prescribing flexibility, and demonstrating drug efficacy.

Altimmune reports strong Q1 performance with promising NASH and obesity results

Altimmune's Q1 2023 performance showcased strong cash reserves, increased R&D investment, and promising results for pemvidutide in NASH and obesity.
The company's focus on Phase 3 readiness, potential partnerships, and innovative antiviral combinations positions it well for future growth and development.
Challenges with trial discontinuation rates and pending data from the Boingo trial require attention, but Altimmune's strengths and opportunities offer a positive outlook.

Altimmune reports promising Q2 results, eyes HepTcell program advancement

Altimmune's Q2 performance reflects financial stability and progress in clinical development.
Strengths lie in promising trial data, strong financial position, and strategic clinical approach.
Challenges include addressing trial effectiveness, clarifying criteria, and monitoring potential effects.
Opportunities exist in liver fat reduction, HepTcell development, and broad immune response selection.

Altimmune reports positive trial results and financial stability in Q3

Altimmune's Q3 2023 performance reflects strong financial position and ongoing research efforts.
Pemvidutide and HepTcell trials show promise in treating obesity, NASH, and HBV.
Analyst interest and positive trial results indicate growth potential for Altimmune.
Focus on innovation and collaboration key to navigating challenges and seizing opportunities.

Altimmune reports promising trial results and seeks strategic partnerships for growth

Altimmune's Q4 performance reflected significant R&D investment and positive trial outcomes.
Strengths lie in pemvidutide's efficacy on liver fat reduction, MRI analysis, and oral formulation progress.
Challenges include partnership agreements, financial losses, and Phase III trial initiation timing.
Opportunities exist in IND development, trial enrollment progress, and strategic partnerships for market growth.

Altimmune reports promising trial results and seeks strategic partnerships

Altimmune's Q1 2024 performance reflects increased R&D expenses leading to a net loss, but the company maintains a strong cash position for future endeavors.
Pemvidutide's promising results in obesity trials position it as a potential best-in-class therapy, while ongoing studies aim to differentiate its use in treating liver conditions.
Despite challenges in partnership and regulatory discussions, Altimmune's compound shows strengths in tolerability and potential for expansion into new indications.

Altimmune reports strong Q3 performance, poised for growth opportunities

Altimmune's Q3 performance reflects financial strength and progress in key trials, positioning the company for future success.
While challenges such as FDA alignment and funding exist, strategic partnerships and additional indications present growth opportunities.
Investor interest remains high, supported by positive trial results and management's strategic focus on advancing the pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Altimmune (NASDAQ: ALT ) stock is one of the top trending tickers this morning, with shares up about 28% as of this writing. This surge comes after the company released results from a 48-week study of pemvidutide, the firm's GLP-1 weight-loss drug.

ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings

NEW YORK, NY / ACCESSWIRE / June 24, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=87060&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune Lawsuit - ALT

Altimmune (NASDAQ: ALT) stock price drifted upwards on Monday amid optimism that it will become a leading player in the weight loss industry. It rose by over 2%, meaning that it has soared by over 25% from the lowest point last week.

Altimmune stock price is still at risk despite Pemvidutide hopes

Full analysis of body composition data showed class-leading lean mass preservation with 21.9% of weight loss attributable to lean mass and 78.1% attributable to fat Full analysis of body composition data showed class-leading lean mass preservation with 21.9% of weight loss attributable to lean mass and 78.1% attributable to fat

Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association's 84th Scientific Sessions

NEW YORK, June 23, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the “Class Period”), of the important July 5, 2024 lead plaintiff deadline.

ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT

NEW YORK, NY / ACCESSWIRE / June 23, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ:ALT) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Altimmune securities between December 1, 2023 and April 26, 2024, inclusive (the "Class Period").

UPCOMING ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit!

Pemvidutide elicited significant weight loss and decreases in pro-inflammatory serum lipids associated with atherogenesis and cardiovascular disease risk Pemvidutide elicited significant weight loss and decreases in pro-inflammatory serum lipids associated with atherogenesis and cardiovascular disease risk

Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association's 84th Annual Scientific Sessions

NEW YORK, NY / ACCESSWIRE / June 21, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=86854&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against Altimmune, Inc. (ALT) Seeking Recovery for Investors - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / June 21, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=86712&wire=1 or contact Joseph E. Levi, Esq.

Contact Levi & Korsinsky by July 5, 2024 Deadline to Join Class Action Against Altimmune, Inc. (ALT)

NEW YORK, NY / ACCESSWIRE / June 20, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=86644&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the “Class Period”), of the important July 5, 2024 lead plaintiff deadline.

TOP RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT

SAN DIEGO, June 20, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Altimmune, Inc. (NASDAQ: ALT) securities between December 1, 2023 and April 26, 2024. Altimmune is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity and liver diseases.

ALTIMMUNE, INC. INVESTORS: Pending Lead Plaintiff Deadline in ALT Securities Fraud Class Action; Stockholders Should Contact Robbins LLP for Information

GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate in a fireside chat at the Piper Sandler 2nd Annual Virtual Obesity Investor Day, being held on June 26, 2024, to discuss key takeaways from the American Diabetes Association's (ADA) Scientific Sessions. Details on the fireside chat are as follows:

Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways

NEW YORK , June 20, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 5, 2024 to Discuss Your Rights - ALT

NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).

ALT LAWSUIT ALERT: The Gross Law Firm Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced oral presentations on pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH, at the American Diabetes Association's (ADA) 84th Scientific Sessions, to be held in Orlando, FL from June 21-24, 2024.

Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association's Scientific Sessions

NEW YORK, NY / ACCESSWIRE / June 18, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=85998&wire=1 or contact Joseph E. Levi, Esq.

Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action - ALT

NEW YORK, NY / ACCESSWIRE / June 17, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=85975&wire=1 or contact Joseph E. Levi, Esq.

Altimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights – ALT

Abbott Labs

DexCom

Regeneron Pharmaceuticals

Weight-loss breakthroughs all emerged from diabetes treatment. Meetings such as the coming American Diabetes Association are increasingly dominated by news on obesity drugs.

New Weight-Loss Drugs and Devices Are Coming This Week

NEW YORK , June 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT

NEW YORK, June 16, 2024 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the “Class Period”), shareholders who want to serve as lead plaintiff for the class must file their motions with the court by July 5, 2024.

ALT ANNOUNCEMENT: If You Have Suffered Losses in Altimmune, Inc. (NASDAQ: ALT), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, NY / ACCESSWIRE / June 16, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ:ALT) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Altimmune securities between December 1, 2023 and April 26, 2024, inclusive (the "Class Period").

UPCOMING ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit

EVgo

Recursion Pharmaceuticals

Low-priced stocks under $10 can be explosively awarding. That is, if you spot the right one at the right time with the right catalyst.

3 Stocks Under $10 Set to Quadruple by 2025: June Edition

NEW YORK, NY / ACCESSWIRE / June 13, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ:ALT) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Altimmune securities between December 1, 2023 and April 26, 2024, inclusive (the "Class Period").

ALT SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit!

Edelson Lechtzin LLP reminds investors who purchased Altimmune, Inc. (NASDAQ: ALT) common stock of the July 5, 2024 deadline to move the Court to appoint them as lead plaintiff in the pending securities fraud class action lawsuit. NEWTOWN, PA / ACCESSWIRE / June 12, 2024 / Edelson Lechtzin LLP, a leading class action law firm, reminds investors who purchased Altimmune, Inc. (NASDAQ:ALT) common stock between December 1, 2023, and April 26, 2024 (the "Class Period") of the July 5, 2024, deadline to move the U.S. District Court for the District of Maryland to appoint them as lead plaintiff in the pending securities fraud class action lawsuit.

News for Altimmune Stock (ALT)